FL-ETT
9.7.2024 20:26:35 CEST | Business Wire | Press release
ETT | iByond™, together with WorldVuer established WorldVuer iByond’s joint venture to develop the world’s first artificial intelligence operating system, WiOS (WorldVuer iByond Operating System). This collaboration is poised to modernize the technology estates of global enterprises, multinationals, sovereigns, and governments, leveraging intelligent interoperability, speed of innovation, AI, and an airtight security platform. “WiOS is poised to be one of the next big players to dominate the world stage alongside Android and iOS,” concluded Mr. Michael Sutton, Chief Media Officer of WorldVuer Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709427149/en/
Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc. & Christopher Condon, Chairman & CEO of ETT | iByond™ (Photo: Business Wire)
ETT | iByond™, renowned for its cutting-edge Intelligent Interoperability AI platform, offers seamless integration and intelligent solutions tailored to enhance business operations across various industries. With a commitment to driving technological advancement, iByond's platform empowers organizations to harness the power of AI, enabling smarter decision-making, improved efficiency, and significant cost savings for enterprises. The iByond platform will serve individual consumers with WorldVuers’ technology products. WorldVuer brings to this venture their existing ecosystem of customers, consisting of 25 countries and 98 Million households, estimated to bring this partnership USD $6 Billion+ in annual software subscription revenues. Additionally, WorldVuer has a diverse portfolio of seven pioneering technologies, each designed to push the boundaries of innovation. WorldVuer’s products are built with an emphasis on security, incorporating airtight cybersecurity measures to ensure the utmost protection for users.
“We are excited to partner with WorldVuer, a company that shares our vision of innovation and excellence,” said Christopher Condon, Chairman and CEO of ETT | iByond™. “This partnership will enable us to deliver an unparalleled AI operating system with the highest level of speed, security, and data connection helping governments and enterprises worldwide to thrive in an increasingly digital world.”
“Innovating an AI Operating System that is built to transition the current global interconnected cloud devices within our communities and countries into an efficient, corroborative, and dynamic Interoperable platform to power current and futuristic devices makes this initiative an exciting opportunity for both WorldVuer and ETT | iByond™,” commented by Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc.
“As we continue to witness extensive adoption and investment in AI across the enterprise and consumer markets globally, the WorldVuer iByond operating system provides breakthrough innovation and value by integrating hardware, software, and platform technologies and services. speed, security, and scale are now in reach at a level far beyond the data management and AI solutions currently available.” Lanny Cohen, Vice-Chairman & CPO, ETT | iByond™
About WorldVuer iByond
At WorldVuer | iByond, a joint venture that provides cutting-edge intelligent technologies powered by the iByond | WiOS system, focused on Enhanced Security, Seamless Data Integration, Improved Data Governance, and Enhanced Collaboration. WorldVuer iByond provides top-tier data protection, smooth data flow, regulatory compliance, and efficient communication, empowering organizations to boost productivity, creativity, and competitiveness. For more information, visit www.worldvueribyond.com
About ETT | iByond™
ETT | iByond™ is a leading provider of transformative solutions for enterprises, specializing in software, infrastructure, and innovations. iByond empowers businesses to embrace digital transformation and unlock new avenues for growth and success in today’s rapidly evolving business environment connecting humanity through intelligent data. For more information, visit www.ettworld.com
About WorldVuer
Leaders in interactive content development. We build products to bring a lifestyle narrative and communications capabilities into your home and office. Buy WorldVuer products and join our new emerging media empowering solutions that help you build success for you and your family. For more information, visit www.wvistore.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709427149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release
Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European
Digital Reef Turns to Vertical Farming to Reduce Data Centre Footprint in Partnership With Elevate Farms and Xange.com to Provide Digital Measurement, Reporting and Verification of Project's Environmental Impact Within the Reef Origin Ecosystem23.10.2026 13:12:00 CEST | Press release
The collaboration leverages Elevate Farms’ proprietary vertical farming technology reducing water consumption, land usage and carbon emissions. Elevate Farms Inc. and Digital Reef Ltd partnership supports mitigating environmental impact of global data centre expansion establishing a framework for Digital Reef’s infrastructure pipeline to support and utilize environmental assets generated by Elevate Farms' high-yield, closed-loop vertical farming operations. Traditional agriculture supply chains are replaced with optimized indoor facilities significantly reducing food production carbon emissions, water waste and local land constraints. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022393352/en/ Elevate Farms technology offers part of the solution to climate impact isolating food production from traditional agricultural farming variables saving over 95% of standard water requirements and significantly reducing farmland req
SLB Announces Third-Quarter 2026 Results23.10.2026 12:50:00 CEST | Press release
Revenue of $9.45 billion increased 5% sequentially and 6% year on year GAAP EPS of $0.49 decreased 6% sequentially and 2% year on year EPS, excluding charges and credits, of $0.64 increased 16% sequentially and decreased 7% year on year Net income attributable to SLB of $735 million decreased 6% sequentially and 1% year on year Adjusted EBITDA of $2.07 billion increased 9% sequentially and was essentially flat year on year Cash flow from operations was $1.51 billion and free cash flow was $828 million Board approved quarterly cash dividend of $0.295 per share SLB (NYSE: SLB) today announced results for the third-quarter 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021694458/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2026Jun. 30, 2026Sept. 30, 2025SequentialYear-on-yearRevenue $9,449 $8,972 $8,928 5
EZVIZ’s Smart Entry Solutions Have Consecutively Clinched the European Product Design Award and the Golden Pin Design Award, Indicating a Shift From Home Security to Living Enjoyment23.10.2026 11:58:00 CEST | Press release
EZVIZ’s smart lock and AI-powered doorbell remained in the spotlight after IFA for bagging two world-class awards. The EP8 Ultra AI-powered video doorbell won the European Product Design Award 2026 (EPDA 2026), keeping leading in user-centric AI. Meanwhile, the DL50FVX smart lock was named the 2026 Golden Pin Design Award (GPDA) laureate for its intuitive access management and entered the finalist of the Best Design Awards. The growing prestige of EZVIZ’s smart home access management lineup marks a new chapter of providing living experiences with multi-level interaction, modern aesthetics, and emotional care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022441786/en/ Two representative models from EZVIZ's smart entry family take home prestigious awards for user-centric innovation. Founded in 2016, the EPDA aims to recognize well-thought-out products that break with tradition and improve everyday life. Continually refres
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines23.10.2026 07:00:00 CEST | Press release
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local clinical trial conducted in China as well as global READY clinical trials, with local results reinforcing that Relfydess delivers significant improvements in frown lines, with a fast onset of action as early as day one, and sustained results for up to six months in some patients3-7 This approval underscores Galderma’s continued leadership in the Asia-Pacific region and further expands the global reach of Relfydess, which is already authorized in more than 35 markets worldwide Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking a significant expansion of the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom